07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Fluorouracil/salicylic acid: Phase III data

Top-line data from a double-blind, German and U.K. Phase III trial in about 166 patients with a 25 cm 2 area of skin on the face, bald scalp or forehead with 4-10 grade 1 or...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

Almirall, Cipher deal

Almirall granted Cipher Canadian commercialization rights to Vaniqa eflornithine and Actikerall fluorouracil/salicylic acid. Almirall will receive an upfront payment of C$450,000 ($360,495) and is eligible for undisclosed sales milestones. Almirall will be responsible...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Clinical News

Actikerall fluorouracil/salicylic acid regulatory update

The Scottish Medicines Consortium recommended the use of Actikerall fluorouracil/salicylic acid from Almirall on the National Health Service (NHS) in Scotland to treat slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (AK) in immunocompetent adult...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Clinical News

Actikerall fluorouracil/salicylic acid regulatory update

Almirall said the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved Actikerall fluorouracil/salicylic acid to treat palpable and/or moderately thick hyperkeratotic actinic keratosis in adults. The company already launched the topical antimitotic agent in...
07:00 , May 16, 2011 |  BC Week In Review  |  Clinical News

Actikerall fluorouracil/salicylic acid regulatory update

Almirall said Germany, the U.K., Austria, Luxemburg, Poland, Czech Republic and Slovakia granted positive recommendations for Actikerall fluorouracil/salicylic acid to treat palpable and/or moderately thick hyperkeratotic actinic keratosis. Almirall said national marketing approvals may be...